FDA Adverse Event Injury Summary report: N

TAXUS LIBERTE PACLITAXEL-ELUTING CORONARY STENT SYSTEM

MDR report key: 1873742 · Received October 19, 2010

Report

Report Number
2134265-2010-04658
Event Type
Injury
Date Received
October 19, 2010
Date of Event
June 16, 2010
Report Date
September 28, 2010
Manufacturer
BOSTON SCIENTIFIC - GALWAY
Product Code
NIQ
PMA / PMN Number
P060008
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4).

Additional Manufacturer Narrative · 1

PATIENTS DATE OF BIRTH (B)(6).

Additional Manufacturer Narrative · 1

DEVICE IS A COMBINATION PRODUCT. DEVICE EVALUATED BY MANUFACTURER. IT IS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION; THEREFORE, A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. A REVIEW OF THE BATCH HISTORY, HISTORICAL TRENDING, AND SIMILAR COMPLAINT TRENDING REVIEW FOR THE PRODUCT FAMILY WILL BE CONDUCTED. IF THERE IS ANY FURTHER RELEVANT INFORMATION FROM THAT REVIEW, A SUPPLEMENTAL MEDWATCH WILL BE FILED. (B)(4).

Description of Event or Problem · 1

SAME CASE AS 2134265-2010-05581 AND 2134265-2010-05582. IT WAS FURTHER REPORTED THAT THE LESION BEING TREATED IN THE INDEX PROCEDURE WAS A 3.00MM, 50.0MM LONG 90% STENOSED. THE PHYSICIAN TREATED THE LESION WITH PRE-DILATATION, AND SUCCESSFULLY IMPLANTING THREE (3.00X28MM, 3.00X12MM AND A 2.50X12MM) TAXUS LIBERTE STENTS WITHOUT GAP, AND POST-DILATATION. RESIDUAL STENOSIS BECAME VISUALLY 0% AND TIMI-3 FLOW HAD BEEN KEPT SINCE PRE-INDEX PROCEDURE. THE PATIENT WAS DISCHARGED WITHOUT COMPLICATIONS TWO DAYS LATER ON ASPIRIN AND CLOPIDOGREL BISULFATE. 264 DAYS POST-INDEX PROCEDURE, THE PATIENT EXPERIENCED ANGINA. PCI WAS PERFORMED. THE TARGET LESION WAS VISUALLY 90% STENOSED. THE PHYSICIAN TREATED THE LESION WITH BALLOON ANGIOPLASTY AND PLACEMENT OF A NON BSC STENT. RESIDUAL STENOSIS BECAME 0%. THE PATIENT WAS DISCHARGED THE NEXT DAY.

Description of Event or Problem · 1

SAME CASE AS 2134265-2010-05581 AND 2134265-2010-05582. IT WAS FURTHER REPORTED THAT THE LESION BEING TREATED IN THE INDEX PROCEDURE WAS A 3.00MM, 50.0MM LONG 90% STENOSED. THE PHYSICIAN TREATED THE LESION WITH PRE-DILATATION, AND SUCCESSFULLY IMPLANTING THREE (3.00X28MM, 3.00X12MM AND A 2.50X12MM) TAXUS LIBERTE STENTS WITHOUT GAP, AND POST-DILATATION. RESIDUAL STENOSIS BECAME VISUALLY 0% AND TIMI-3 FLOW HAD BEEN KEPT SINCE PRE-INDEX PROCEDURE. THE PATIENT WAS DISCHARGED WITHOUT COMPLICATIONS TWO DAYS LATER ON ASPIRIN AND CLOPIDOGREL BISULFATE. AT 264 DAYS POST-INDEX PROCEDURE, THE PATIENT EXPERIENCED ANGINA. PCI WAS PERFORMED. THE TARGET LESION WAS VISUALLY 90% STENOSED. THE PHYSICIAN TREATED THE LESION WITH BALLOON ANGIOPLASTY AND PLACEMENT OF A NON BSC STENT. RESIDUAL STENOSIS BECAME 0%. THE PATIENT WAS DISCHARGED THE NEXT DAY.

Description of Event or Problem · 1

(B)(4). IT WAS REPORTED THAT FOLLOWING A CORONARY ARTERY TREATMENT PROCEDURE THE PATIENT EXPERIENCED ANGINA. THE LESION BEING TREATED WAS LOCATED IN THE MID LEFT ANTERIOR DESCENDING ARTERY. THE PHYSICIAN IMPLANTED A TAXUS LIBERTE STENT OF UNKNOWN SIZE IN THE LESION. IN (B)(6) 2010, THE PATIENT DEVELOPED ANGINA PECTORIS. NINE-MONTH FOLLOW-UP ANGIOGRAPHY WAS PERFORMED. RESULTS REVEALED THE TARGET VESSEL DIAMETER WAS 3.00MM, 35MM LONG WITH 90% STENOSIS. THE PHYSICIAN PERFORMED A TVR USING AN UNKNOWN BALLOON CATHETER AND UNKNOWN SIZE NON BSC STENT WITH RESIDUAL STENOSIS BEING 0%. THE PATIENT WAS DISCHARGED 2 DAYS LATER WITH THE PATIENTS SYMPTOMS IMPROVED. THERE WAS NO ANGINAL SYMPTOMS REPORTED AT THE 1 YEAR FOLLOW-UP.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TAXUS LIBERTE PACLITAXEL-ELUTING CORONARY STENT SYSTEM CORONARY DRUG-ELUTING STENT NIQ BOSTON SCIENTIFIC - GALWAY H7493893628300

Patients

Seq Age Sex Outcome Treatment
1 79 YR Required Intervention 3.00X12MM TAXUS LIBERTE STENT| 2.50X12MM TAXUS LIBERTE STENT